Search

PTC Therapeutics Inc

Closed

SectorHealthcare

68.92 1.76

Overview

Share price change

24h

Current

Min

66.72

Max

69.45

Key metrics

By Trading Economics

Income

-135M

-52M

Sales

-2.7M

358M

P/E

Sector Avg

7.597

51.78

EPS

0.61

Profit margin

-14.447

Employees

991

EBITDA

-140M

22M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+46.8% upside

Market Stats

By TradingEconomics

Market Cap

-11M

5.1B

Previous open

67.16

Previous close

68.92

PTC Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

4 Nov 2026, 20:26 UTC

Correlated Moves

PTC Therapeutics shares are modestly higher, supported by advances in the iShares Biotechnology ETF following positive news on Moderna's mRNA vaccine candidate.

3 Nov 2026, 21:02 UTC

Social Media
News

PTC Therapeutics' Board approved a $500 million share repurchase program, reflecting confidence in growth prospects and generating positive sentiment around the stock.

2 Nov 2026, 21:09 UTC

News

Citigroup reaffirms Buy rating on PTC Therapeutics and raises price target to $109, as the company prepares for upcoming investor conferences.

30 Oct 2026, 20:04 UTC

Social Media
News

PTC Therapeutics reported a Q3 2026 net loss of $51.7 million and a basic EPS of -$0.62, overshadowing positive analyst ratings and price target increases.

29 Oct 2026, 20:13 UTC

News

PTC Therapeutics reported a Q3 2026 net loss of $51.7 million, missing EPS estimates despite revenue of $358 million and raising full-year guidance to $1.29 to $1.32 billion.

28 Oct 2026, 19:36 UTC

PTC Therapeutics, Inc. is trading higher, having reached a peak cumulative return, consistent with three consecutive daily advances.

27 Oct 2026, 20:07 UTC

Correlated Moves

PTC Therapeutics is trading higher, supported by positive momentum in the biotechnology sector and gains in the SPDR S&P Biotech ETF.

23 Oct 2026, 20:01 UTC

PTC Therapeutics Inc shares are declining, reversing the recent trend of higher daily closes since Thursday's close.

20 Oct 2026, 20:08 UTC

Correlated Moves

PTC Therapeutics Inc is advancing, reflecting a broader positive trend in biotechnology stocks as the SPDR S&P Biotech ETF (XBI) also moves higher.

19 Oct 2026, 20:01 UTC

PTC Therapeutics Inc shares are advancing despite a broader market downturn, continuing the upward momentum observed in recent sessions.

15 Oct 2026, 20:02 UTC

News
Correlated Moves

UBS analyst Joon Lee raised the price target on PTC Therapeutics Inc to $90.00 from $80.00 while maintaining a Buy rating.

13 Oct 2026, 20:01 UTC

PTC Therapeutics Inc shares fell sharply, continuing a decline near the low end of their one-month range and below the 20-day moving average.

9 Oct 2026, 20:01 UTC

Correlated Moves

PTC Therapeutics Inc shares are advancing, recovering from an earlier dip, as the iShares Biotechnology ETF also rises, supported by strong gains in key holdings.

8 Oct 2026, 20:07 UTC

Correlated Moves
News

RBC Capital maintains its Sector Perform rating on PTC Therapeutics and lowers its price target to $75, contributing to the stock's decline.

6 Oct 2026, 20:07 UTC

PTC Therapeutics Inc's shares are trading roughly flat, retracing from earlier gains and remaining below the 20-day moving average amid a routine biotechnology sector performance.

28 Sept 2026, 20:01 UTC

PTC Therapeutics Inc. is higher in Monday's trading session, continuing gains since Friday's close, despite an earlier pullback from a session high.

25 Sept 2026, 20:01 UTC

PTC Therapeutics Inc is advancing as the broader market gains, despite earlier pulling back from a session high amid rising Treasury yields and weak consumer sentiment.

24 Sept 2026, 20:07 UTC

PTC Therapeutics Inc. shares fell, closing below the 20-day moving average and near the lower end of its one-month range after midday fluctuations.

23 Sept 2026, 20:02 UTC

Correlated Moves

PTC Therapeutics Inc shares fell sharply amid a broader downturn in the biotechnology sector, influenced by significant losses in the Direxion Daily S&P Biotech Bull 3X ETF.

18 Sept 2026, 20:02 UTC

PTC Therapeutics Inc shares fell sharply, reversing a trend of higher daily closes seen in recent sessions, despite no specific news impacting the company.

16 Sept 2026, 19:06 UTC

News

PTC Therapeutics gained after Leerink Partners initiated coverage with an "outperform" rating and a $98.00 price target, while Jefferies and Citigroup upgraded their ratings.

14 Sept 2026, 20:08 UTC

News

Leerink has initiated coverage on PTC Therapeutics with an Outperform rating and a $98.00 price target, supporting a higher trading session since Friday's close.

11 Sept 2026, 19:56 UTC

Social Media

PTC Therapeutics Inc shares are lower today amid discussions from an investor event and plans for a Biologics License Application for a Fabry disease treatment.

10 Sept 2026, 23:41 UTC

PTC Therapeutics Inc shares are higher in after-market trading, gradually increasing since Thursday's close, despite remaining below their 20-day moving average.

8 Sept 2026, 20:07 UTC

Correlated Moves

Shares lower amid decline in iShares Biotechnology ETF.

2 Sept 2026, 20:08 UTC

PTC Therapeutics Inc. is gaining today, supported by a broader advance in biotechnology stocks, despite a pullback earlier in the session.

31 Aug 2026, 19:46 UTC

PTC Therapeutics shares are lower today, continuing a recent decline amid broader market unease following hawkish comments from Federal Reserve Chair Kevin Warsh.

28 Aug 2026, 23:36 UTC

PTC Therapeutics Inc shares are higher in after-market hours, recovering from an earlier dip. No specific news was identified to explain the movement.

27 Aug 2026, 20:07 UTC

PTC Therapeutics shares are lower today, continuing a decline since Wednesday's close, despite positive labor market data. No specific news was identified.

25 Aug 2026, 20:09 UTC

Event
Correlated Moves

PTC Therapeutics shares are higher as the company announces multiple data presentations for Sephience™ at an upcoming symposium in Helsinki.

Peer Comparison

Price change

PTC Therapeutics Inc Forecast

Price Target

By TipRanks

46.8% upside

12 Months Forecast

Average 100 USD  46.8%

High 137 USD

Low 62 USD

Based on 12 Wall Street analysts offering 12 month price targets forPTC Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

10

Buy

2

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
help-icon Live chat